Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer

Journal of Infection

Volumn 64, Issue 1, 2012, Pages 68-75

  Chitasombat, Maria N ^a   Kofteridis, Diamantis P ^a   Jiang, Ying ^a   Tarrand, Jeffrey ^a   Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Cancer; Immunosuppression; Non Candida yeast

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANCER PATIENT; CANDIDA; CATHETER REMOVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; FUNGEMIA; FUNGUS; FUNGUS ISOLATION; GEOTRICHUM; HUMAN; INCIDENCE; MALASSEZIA; MALE; MINIMUM INHIBITORY CONCENTRATION; NON CANDIDA YEAST; NONHUMAN; PICHIA; RETROSPECTIVE STUDY; RHODOTORULA; RISK FACTOR; RISK REDUCTION; SACCHAROMYCES CEREVISIAE; SCHOOL CHILD; SURVIVAL RATE; TRICHOSPORON; YEAST BLOODSTREAM INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CATHETER-RELATED INFECTIONS; CHILD; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YEASTS; YOUNG ADULT;

EID: 84455202347     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.11.002     Document Type: Article

References (36)

1. Kontoyiannis D.P., Torres H.A., Chagua M., Hachem R., Tarrand J.J., Bodey G.P., et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004, 36:564-569.
2. Miceli M.H., Diaz J.A., Lee S.A. Emerging opportunistic yeast infections. Lancet Infect Dis 2011, 11:142-151.
3. Goodman D., Pamer E., Jakubowski A., Morris C., Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002, 35:35-36.
4. Matsue K., Uryu H., Koseki M., Asada N., Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006, 42:753-757.
5. Henrich T.J., Marty F.M., Milner D.A., Thorner A.R. Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. Transplant Infect Dis 2009, 11:458-462.
6. Girmenia C., Pagano L., Martino B., D'Antonio D., Fanci R., Specchia G., et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005, 43:1818-1828.
7. Cairoli R., Marenco P., Perego R., de Cataldo F. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transplant 1995, 15:785-786.
8. Vazquez J. Rhodotorula, Malassezia, Trichosporon and other yeast-like fungi. Clinical mycology 2003, Oxford University Press, New York, pp. 203-17.
9. Bryce E.A., Roberts F.J., Sekhon A.S., Coldman A.J. Yeast in blood cultures. Evaluation of factors influencing outcome. Diagn Microbiol Infect Dis 1992, 15:233-237.
10. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
11. CLSI Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard 2008, CLSI document M27-A3, Clinical and Laboratory Standards Institute, Wayne, PA. 3rd ed.
12. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., Rex J.H., Alexander B.D., Andes D., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008, 46:2620-2629.
13. Hazen K., Howell S.A. Candida, Cryptococcus and other yeasts of medical importance. Manual of clinical microbiology 2007, ASM Press, Washington DC. 9th ed.
14. Larone D. Medically important fungi: a guide to identification 2002, ASM Press, Washington, D.C. 4th ed.
15. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
16. Duthie R., Denning D.W. Aspergillus fungemia: report of two cases and review. Clin Infect Dis 1995, 20:598-605.
17. Lionakis M.S., Bodey G.P., Tarrand J.J., Raad, Kontoyiannis D.P. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin Microbiol Infect 2004, 10:922-925.
18. Segal B.H., Herbrecht R., Stevens D.A., Ostrosky-Zeichner L., Sobel J., Viscoli C., et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
19. Antoniadou A., Torres H.A., Lewis R.E., Thornby J., Bodey J.P., Han X.Y., et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003, 82:309-321.
20. Anatoliotaki M., Mantadakis E., Galanakis E., Samonis G. Rhodotorula species fungemia: a threat to the immunocompromised host. Clin Lab 2003, 49:49-55.
21. Kiehn T.E., Gorey E., Brown A.E., Edwards F.F., Armstrong D. Sepsis due to Rhodotorula related to use of indwelling central venous catheters. Clin Infect Dis 1992, 14:841-846.
22. Tuon F.F., de Almeida G.M., Costa S.F. Central venous catheter-associated fungemia due to Rhodotorula spp. - a systematic review. Med Mycol 2007, 45:441-447.
23. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Bijie H., et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: an 10.5-year analysis of susceptibilities of Non-Candida yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009, 47:117-123.
24. Elvers K.T., Leeming K., Lappin-Scott H.M. Binary and mixed population biofilms: time-lapse image analysis and disinfection with biocides. J Ind Microbiol Biotechnol 2002, 29:331-338.
25. Munoz P., Bouza E., Cuenca-Estrella M., Eiros J.M., Perez M.J., Sanchez-Somolinos, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005, 40:1625-1634.
26. Bayramoglu G., Sonmez M., Tosun I., Aydin K., Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 2008, 36:68-70.
27. Diekema D.J., Petroelje B., Messer S.A., Hollis R.J., Pfaller M.A. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005, 43:476-478.
28. Lunardi L.W., Aquino V.R., Zimerman R.A., Goldani L.Z. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006, 43:60-63.
29. Walsh T.J., Newman K.R., Moody M., Wharton R.C., Wade J.C. Trichosporonosis in patients with neoplastic disease. Medicine 1986, 65:268-279.
30. Falk R., Wolf D.G., Shapiro M., Polacheck I. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol 2003, 41:911.
31. Perparim K., Nagai H., Hashimoto A., Goto Y., Tashiro T., Nasu M. In vitro susceptibility of Trichosporon beigelii to antifungal agents. J Chemother 1996, 8:445-448.
32. Walsh T.J., Melcher G.P., Rinaldi M.G., Lecciones J., McGough D.A., Kelly P., et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990, 28:1616-1622.
33. Anaissie E., Gokaslan A., Hachem R., Rubin R., Griffin G., Robinson R., et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992, 15:781-787.
34. Paphitou N.I., Ostrosky-Zeichner L., Paetznick V.L., Rodriguez J.R., Chen E., Rex J.H. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002, 46:1144-1146.
35. Pfaller M., Diekema D. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53.
36. Sipsas N.V., Lewis R.E., Tarrand J., Hachem R., Rolston K.V., Raad, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752.